Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging

Fig. 5

Ex vivo validation on excised BT-474 and JIMT-1 tumors confirm positron emission tomography (PET) uptake. Western blots were performed for human epidermal growth factor receptor 2 (HER2), Src, and phosphorylated Src (pSrc) (Y416) expression using BT-474 tumor lysates (a); a plot of the pSrc (Y416) densitometry showed a linear relationship with 89Zr-trastuzumab PET uptake (b). A plot of the pHER2 (Y1221) densitometry showed a linear relationship with 89Zr-trastuzumab PET uptake (c). Similarly, JIMT-1 tumors obtained after PET was lysed and analyzed for protein expression using western blots (d). pSrc (Y416) also demonstrated a direct linear correlation with 89Zr-trastuzumab PET uptake in JIMT-1 tumors (e). A plot of the pHER2 (Y1221) densitometry showed a linear relationship with 89Zr-trastuzumab PET uptake (f). All densitometry values were obtained as the ratio of total protein to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)

Back to article page